Cardiovascular DiseasesALLSTARNCT05176756
RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)
A study testing Gamification and Social Support in people with Cardiovascular Diseases and Breast Cancer, run by Abramson Cancer Center at Penn Medicine at 2 sites in United States.
Trial summary
This is a two-arm, randomized, controlled trial to evaluate the effectiveness of using a behaviorally designed gamification intervention with social support compared to an attention control group to increase physical activity during a 6-month intervention with a 3-month follow-up period. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiovascular Diseases, Breast Cancer, Prostate Cancer
- What is being tested?
- Gamification and Social Support
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 2 sitesUnited States
- Study dates
- 14 Apr 2022to 18 Feb 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have been diagnosed with breast or prostate cancer and treated with cardiotoxic therapy (e.g. anthracyclines, chest radiation, trastuzumab, aromatase inhibitors, or ADT)
- Have ≥1 cardiovascular risk factors (e.g. hypertension, diabetes, dyslipidemia, obesity) or known coronary artery disease (prior coronary revascularization, myocardial infarction, or coronary stenosis > 70%), or are 65+ years of age at time of enrollment
- Self-identify as Black or Hispanic
- Are at least 2 years from their cancer diagnosis and have no evidence of active malignancy or acute illness that would limit study participation
- Own a smartphone or tablet compatible with the wearable device
- Are able to read English or Spanish
- Are able to provide informed consent
Who cannot join
- Currently participating in another physical activity research study
- Have any medical conditions prohibiting ambulation without assistance
- Any other reason why it is not feasible or safe to complete the entire 9-month study
- Step count > 7500/day during the baseline data collection period
Trial locations and contacts
2 sites in 1 country.
United States2 sites
City of Hope National Medical Center
Duarte, California, 91010
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
About this study
Official title: A Randomized Controlled Trial of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)
This is a two-arm, randomized, controlled trial to evaluate the effectiveness of using a behaviorally designed gamification intervention with social support compared to an attention control group to increase physical activity during a 6-month intervention with a 3-month follow-up period. We will enroll 150 Black or Hispanic breast and prostate cancer survivors who are at an especially high risk for developing major CVD from two U.S. cancer centers: the University of Pennsylvania Health System and City of Hope National Medical Center. All participants will receive a wearable activity tracker (Fitbit) and will be enrolled in the Way to Health system, a research information technology platform at the University of Pennsylvania. Within the Way to Health platform, patients will set a goal to increase daily step count from baseline, and will then be randomized to gamification plus social support or to attention control. The study will evaluate the effect of the gamification intervention on daily physical activity (as measured by daily steps and moderate to vigorous physical activity), physical function, fatigue, and health-related quality of life.
Read the detailed description
The specific objectives of this study are the following:
- To determine the effectiveness of a behaviorally designed gamification intervention with social support to increase physical activity in Black and Hispanic breast and prostate cancer survivors
- To evaluate the effects of the gamification intervention on physical function, fatigue, and health-related quality of life
Recruitment: Participants will be recruited from the tumor registries at the two cancer centers or via direct referral from these two health systems. Patients identified from tumor registries will be emailed a link to the study, after obtaining provider permission to contact. Patients will then be contacted by phone two weeks later to further discuss the study. Interested patients will visit the study website on the Way to Health platform to learn more about the study, create an account, provide informed consent, and complete initial baseline eligibility surveys. Study coordinators will be available to assist patients with this process, as necessary.
Informed Consent: We will follow an IRB-approved approach taken by many studies using the Way to Health platform to obtaining informed consent. Upon reaching the portal, potential participants will be asked to create an account and will then be informed of the details of the study, including its objectives, duration, requirements, and financial payments. The Way to Health portal will then take interested participants through an online informed consent. Successive screens will explain the voluntary nature of the study, the risks and benefits of participation, alternatives to participation, and that participants can withdraw from the study at any time. On the final consent screen, potential participants who click a clearly delineated button stating that they agree to participate in the study will be considered to have consented to enroll. Participants will be provided with details regarding how to contact the research team via email or phone at any time if they subsequently wish to withdraw from the study. Support partners will provide verbal informed consent via telephone for their name, email address, and phone number to be stored in the study database. For participants who are English-speaking but illiterate, an authorized family member will be present to witness the oral presentation of the consent form and both participant and authorized family member sign the consent form. Spanish speaking patients will be consented with the aid of a medical interpreter. Directly referred patients will also complete informed consent via the Way to Health platform as above.
Enrollment: Immediately after completing the informed consent process, potentially eligible patients will be prescreened to ensure they meet the eligibility criteria. Simultaneously, participants will complete an online questionnaire to confirm eligibility and complete the study surveys.
Study surveys: The baseline questionnaire will include demographics, as well as validated surveys on health status, exercise self-efficacy, other forms of exercise besides step counts (e.g. swimming, biking), and health-related quality of life (EQ-5D-5L). To assess physical function and fatigue, they will complete the Patient Reported Outcome Measure Information System (PROMIS) Physical Function, Global-10 scales, 6b, and Cancer Fatigue Short Form scales. We will also assess the social determinants of health (SDOH) through a validated, reliable and reproducible instrument focused on the core, structural, and individual SDOH.
Determination of Baseline Step Count and Goal-Setting: After completing the baseline questionnaire, eligible participants will be mailed a wearable activity tracking device and asked to get used to the wearable device for a few weeks. During this run-in period, baseline activity measures (daily step counts, minutes of moderate-to-vigorous physical activity, minutes of sleep) will be estimated. If fewer than 4 days of data are available during the second week, study coordinators will reach out to the participant to inquire about any device issues and the run-in period will be extended until at least 4 days of data are captured. Participants who do not complete this run-in phase will not be randomized into the trial, nor will patients with step counts > 7500 steps/day during the run-in phase. Once baseline measures have been established, eligible participants will be contacted to choose a goal step goal increase between 1500 to 3000 steps above their baseline. Participants will be able to adjust their step goal at any time during the study, as long as it is within this range.
Randomization: Participants that have established baseline measures and finished goal selection will be randomly assigned to control or the intervention using a 1:1 allocation, stratifying by site (Penn or City of Hope) and on baseline step count (<4000, 4000-5999, 6000-7500), and block sizes of 2 using an electronic number generator through the Way to Health platform.
End-of-study: At the end of the 6-month intervention and 3-month follow-up period, patients will be alerted by the Way to Health platform to return to the study website to complete an end-of-study questionnaire consisting of the EQ-5D-5L, PROMIS Physical Function and Global-10 scales, the PROMIS Cancer Fatigue Short Form, and the Godin Leisure Time exercise questionnaire.
Subject compensation: To reduce dropout and the risk of differential attrition by arm, all participants will receive $25 for enrolling in the study, $25 for completing 6-months, and $50 for completing 9 months (total of $100).
Data analyses: Data for all consented patients, whether or not they completed all protocol requirements, will be included for analysis. All analyses will be performed by faculty and staff statisticians at the University of Pennsylvania using intention-to-treat and will be adjusted for the stratification factors used at randomization. A two-sided Type I error=0.05 will be used.
- Being tested
- Gamification and Social Support, Attention control
- Keywords
- physical activity, cardiovascular disease, randomized controlled trial, breast cancer, prostate cancer
- Medical subject headings
- Cardiovascular Diseases, Breast Neoplasms, Prostatic Neoplasms, Sedentary Behavior, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gamification and Social SupportBehavioural
Participants will be entered into a points and levels-based game designed to help them meet their step count goals. At the start of each week, the participant will receive a set amount of points. Each day their step goal is not met, they lose points. If the participant meets a certain point value at the end of the week, they will either advance one level (of five total levels); if they do not, they will drop one level. Each participant will also select a family member or friend or the study coordinator to serve as a support partner. At the beginning of the intervention, the participant and support partner will identify at least 3 ways in which they can help the participant meet their step goals. This partner will receive a weekly email reminding them of these approaches and updating them on the participant's progress.
Attention controlBehavioural
Participants will receive a daily text message with their step count from the day prior.
| Study group | Role | What they receive |
|---|---|---|
| Attention Control | Active comparator | In addition to using a wearable device, participants in this arm will receive a daily notification of their step count from the previous day. This notification serves as an 'attention control' and allows us to better isolate the impact of the gamification with social support. It may also help to reduce differential attrition across arms. Receives: Behavioral: Attention control |
| Gamification and Social Support | Experimental | Participants in this arm will receive the same devices and daily messaging as control. They will also be entered into a game designed using behavioral economic principles for 6 months. This intervention has been adapted from our prior successful pilot studies. The game runs automatically and does not require any effort on the part of the participant to 'play' the game other than to strive for physical activity goals. Participants in this arm will also select a family member or friend who will serve as a support partner to encourage the participant to meet their step goals. The gamification and social support interventions will end after 6 months at which point participants will receive the same treatment as the attention control arm for the 3-month follow-up period. Receives: Behavioral: Gamification and Social Support |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in daily step count
Change in daily step count for patients in intervention arm versus patients in the attention control arm
Measured: Baseline to the 6-month intervention period
Secondary outcomes (3)
Change in daily step count
Change in daily step count for patients in intervention arm versus patients in the attention control arm
Measured: Baseline to the 3-month follow-up period
Change in daily minutes of moderate or vigorous physical activity (MVPA)
Change in daily minutes of moderate or vigorous physical activity in patients in intervention arm versus patients in the attention control arm
Measured: Baseline to the 6-month intervention period
Change in daily minutes of moderate or vigorous physical activity (MVPA)
Change in daily minutes of moderate or vigorous physical activity in patients in intervention arm versus patients in the attention control arm
Measured: Baseline to the 3-month follow-up period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jan 2022
- Study start14 Apr 2022
- Primary completion11 Nov 2024
- Study completion18 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by Abramson Cancer Center at Penn MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- American Heart Association, City of Hope National Medical Center
- Responsible party
- Sponsor
- Investigators
- Kevin Volpp, MD, PhD, Principal investigator, University of PennsylvaniaAlexander C. Fanaroff, MD, Principal investigator, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05176756
- Sponsor's protocol ID
- UPCC 21921
- Other IDs
- 849679
- Acronym
- ALLSTAR
- Status last verified
- Jul 2025
- First submitted
- 15 Dec 2021
- Last updated
- 1 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Fanaroff AC, Orr JA, Anucha C, Kim E, Rareshide C, Zhu J, Echevarria M, Rodarte S, Kassabian M, Balasian E, Ky B, Volpp KG, Armenian SH. Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors. JACC CardioOncol. 2025 Dec;7(7):816-828. doi: 10.1016/j.jaccao.2025.10.001. Epub 2025 Nov 3.
PubMed 41182202Fanaroff AC, Orr JA, Anucha C, Kim E, Rareshide C, Echevarria M, Rodarte S, Kassabian M, Balasian E, Ky B, Volpp KGM, Armenian S. A randomized controlled trial of gamification to increase physical activity among black and Hispanic breast and prostate cancer survivors: Rationale and design of the ALLSTAR clinical trial. Am Heart J. 2025 Feb;280:42-51. doi: 10.1016/j.ahj.2024.10.021. Epub 2024 Nov 4.
PubMed 39505121Barrett M, Wilcox NS, Huang A, Levy R, Demissei B, Narayan V, Ky B. Bearing allostatic load: insights into a more equitable future within cardio-oncology. Trends Mol Med. 2022 Dec;28(12):1040-1049. doi: 10.1016/j.molmed.2022.09.006. Epub 2022 Oct 4.
PubMed 36207229
Study at a glance
From the registry record, last updated by the sponsor on 1 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)
- ClinicalTrials.gov ID
- NCT05176756
- Acronym / sponsor ID
- ALLSTAR / UPCC 21921
- Keywords
- physical activity, cardiovascular disease, randomized controlled trial, breast cancer, prostate cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Abramson Cancer Center at Penn MedicineUniversity, hospital or other
- Collaborators
- American Heart Association, City of Hope National Medical Center
- Study start
- 14 Apr 2022 (actual)
- Primary completion
- 11 Nov 2024 (actual)
- Study completion
- 18 Feb 2025 (actual)
- First posted
- 4 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a two-arm, randomized, controlled trial to evaluate the effectiveness of using a behaviorally designed gamification intervention with social support compared to an attention control group to increase physical activity during a 6-month intervention with a 3-month follow-up period. We will enroll 150 Black or Hispanic breast and prostate cancer survivors who are at an especially high risk for developing major CVD from two U.S. cancer centers: the University of Pennsylvania Health System and City of Hope National Medical Center. All participants will receive a wearable activity tracker (Fitbit) and will be enrolled in the Way to Health system, a research information technology platform at the University of Pennsylvania. Within the Way to Health platform, patients will set a goal to increase daily step count from baseline, and will then be randomized to gamification plus social support or to attention control. The study will evaluate the effect of the gamification intervention on daily physical activity (as measured by daily steps and moderate to vigorous physical activity), physical function, fatigue, and health-related quality of life.
Detailed description
The specific objectives of this study are the following:
- To determine the effectiveness of a behaviorally designed gamification intervention with social support to increase physical activity in Black and Hispanic breast and prostate cancer survivors
- To evaluate the effects of the gamification intervention on physical function, fatigue, and health-related quality of life
Recruitment: Participants will be recruited from the tumor registries at the two cancer centers or via direct referral from these two health systems. Patients identified from tumor registries will be emailed a link to the study, after obtaining provider permission to contact. Patients will then be contacted by phone two weeks later to further discuss the study. Interested patients will visit the study website on the Way to Health platform to learn more about the study, create an account, provide informed consent, and complete initial baseline eligibility surveys. Study coordinators will be available to assist patients with this process, as necessary.
Informed Consent: We will follow an IRB-approved approach taken by many studies using the Way to Health platform to obtaining informed consent. Upon reaching the portal, potential participants will be asked to create an account and will then be informed of the details of the study, including its objectives, duration, requirements, and financial payments. The Way to Health portal will then take interested participants through an online informed consent. Successive screens will explain the voluntary nature of the study, the risks and benefits of participation, alternatives to participation, and that participants can withdraw from the study at any time. On the final consent screen, potential participants who click a clearly delineated button stating that they agree to participate in the study will be considered to have consented to enroll. Participants will be provided with details regarding how to contact the research team via email or phone at any time if they subsequently wish to withdraw from the study. Support partners will provide verbal informed consent via telephone for their name, email address, and phone number to be stored in the study database. For participants who are English-speaking but illiterate, an authorized family member will be present to witness the oral presentation of the consent form and both participant and authorized family member sign the consent form. Spanish speaking patients will be consented with the aid of a medical interpreter. Directly referred patients will also complete informed consent via the Way to Health platform as above.
Enrollment: Immediately after completing the informed consent process, potentially eligible patients will be prescreened to ensure they meet the eligibility criteria. Simultaneously, participants will complete an online questionnaire to confirm eligibility and complete the study surveys.
Study surveys: The baseline questionnaire will include demographics, as well as validated surveys on health status, exercise self-efficacy, other forms of exercise besides step counts (e.g. swimming, biking), and health-related quality of life (EQ-5D-5L). To assess physical function and fatigue, they will complete the Patient Reported Outcome Measure Information System (PROMIS) Physical Function, Global-10 scales, 6b, and Cancer Fatigue Short Form scales. We will also assess the social determinants of health (SDOH) through a validated, reliable and reproducible instrument focused on the core, structural, and individual SDOH.
Determination of Baseline Step Count and Goal-Setting: After completing the baseline questionnaire, eligible participants will be mailed a wearable activity tracking device and asked to get used to the wearable device for a few weeks. During this run-in period, baseline activity measures (daily step counts, minutes of moderate-to-vigorous physical activity, minutes of sleep) will be estimated. If fewer than 4 days of data are available during the second week, study coordinators will reach out to the participant to inquire about any device issues and the run-in period will be extended until at least 4 days of data are captured. Participants who do not complete this run-in phase will not be randomized into the trial, nor will patients with step counts > 7500 steps/day during the run-in phase. Once baseline measures have been established, eligible participants will be contacted to choose a goal step goal increase between 1500 to 3000 steps above their baseline. Participants will be able to adjust their step goal at any time during the study, as long as it is within this range.
Randomization: Participants that have established baseline measures and finished goal selection will be randomly assigned to control or the intervention using a 1:1 allocation, stratifying by site (Penn or City of Hope) and on baseline step count (<4000, 4000-5999, 6000-7500), and block sizes of 2 using an electronic number generator through the Way to Health platform.
End-of-study: At the end of the 6-month intervention and 3-month follow-up period, patients will be alerted by the Way to Health platform to return to the study website to complete an end-of-study questionnaire consisting of the EQ-5D-5L, PROMIS Physical Function and Global-10 scales, the PROMIS Cancer Fatigue Short Form, and the Godin Leisure Time exercise questionnaire.
Subject compensation: To reduce dropout and the risk of differential attrition by arm, all participants will receive $25 for enrolling in the study, $25 for completing 6-months, and $50 for completing 9 months (total of $100).
Data analyses: Data for all consented patients, whether or not they completed all protocol requirements, will be included for analysis. All analyses will be performed by faculty and staff statisticians at the University of Pennsylvania using intention-to-treat and will be adjusted for the stratification factors used at randomization. A two-sided Type I error=0.05 will be used.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Attention Control | Active comparator | Behavioral: Attention controlIn addition to using a wearable device, participants in this arm will receive a daily notification of their step count from the previous day. This notification serves as an 'attention control' and allows us to better isolate the impact of the gamification with social support. It may also help to reduce differential attrition across arms. |
| Gamification and Social Support | Experimental | Behavioral: Gamification and Social SupportParticipants in this arm will receive the same devices and daily messaging as control. They will also be entered into a game designed using behavioral economic principles for 6 months. This intervention has been adapted from our prior successful pilot studies. The game runs automatically and does not require any effort on the part of the participant to 'play' the game other than to strive for physical activity goals. Participants in this arm will also select a family member or friend who will serve as a support partner to encourage the participant to meet their step goals. The gamification and social support interventions will end after 6 months at which point participants will receive the same treatment as the attention control arm for the 3-month follow-up period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Have been diagnosed with breast or prostate cancer and treated with cardiotoxic therapy (e.g. anthracyclines, chest radiation, trastuzumab, aromatase inhibitors, or ADT)
- Have ≥1 cardiovascular risk factors (e.g. hypertension, diabetes, dyslipidemia, obesity) or known coronary artery disease (prior coronary revascularization, myocardial infarction, or coronary stenosis > 70%), or are 65+ years of age at time of enrollment
- Self-identify as Black or Hispanic
- Are at least 2 years from their cancer diagnosis and have no evidence of active malignancy or acute illness that would limit study participation
- Own a smartphone or tablet compatible with the wearable device
Key exclusion criteria (4 listed)
- Currently participating in another physical activity research study
- Have any medical conditions prohibiting ambulation without assistance
- Any other reason why it is not feasible or safe to complete the entire 9-month study
- Step count > 7500/day during the baseline data collection period
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gamification and Social SupportParticipants will be entered into a points and levels-based game designed to help them meet their step count goals. At the start of each week, the participant will receive a set amount of points. Each day their step goal is not met, they lose points. If the participant meets a certain point value at the end of the week, they will either advance one level (of five total levels); if they do not, they will drop one level. Each participant will also select a family member or friend or the study coordinator to serve as a support partner. At the beginning of the intervention, the participant and support partner will identify at least 3 ways in which they can help the participant meet their step goals. This partner will receive a weekly email reminding them of these approaches and updating them on the participant's progress. | Behavioural | Gamification and Social Support |
| Attention controlParticipants will receive a daily text message with their step count from the day prior. | Behavioural | Attention Control |
Primary outcome
Change in daily step count
Time frame: Baseline to the 6-month intervention period
Change in daily step count for patients in intervention arm versus patients in the attention control arm
3 secondary outcomes
Change in daily step count
Time frame: Baseline to the 3-month follow-up period
Change in daily minutes of moderate or vigorous physical activity (MVPA)
Time frame: Baseline to the 6-month intervention period
Change in daily minutes of moderate or vigorous physical activity (MVPA)
Time frame: Baseline to the 3-month follow-up period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Aug 2025.
- Derived from this study: PubMed 41182202Fanaroff AC, Orr JA, Anucha C, Kim E, Rareshide C, Zhu J, Echevarria M, Rodarte S, Kassabian M, Balasian E, Ky B, Volpp KG, Armenian SH. Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors. JACC CardioOncol. 2025 Dec;7(7):816-828. doi: 10.1016/j.jaccao.2025.10.001. Epub 2025 Nov 3.
- Derived from this study: PubMed 39505121Fanaroff AC, Orr JA, Anucha C, Kim E, Rareshide C, Echevarria M, Rodarte S, Kassabian M, Balasian E, Ky B, Volpp KGM, Armenian S. A randomized controlled trial of gamification to increase physical activity among black and Hispanic breast and prostate cancer survivors: Rationale and design of the ALLSTAR clinical trial. Am Heart J. 2025 Feb;280:42-51. doi: 10.1016/j.ahj.2024.10.021. Epub 2024 Nov 4.
- Derived from this study: PubMed 36207229Barrett M, Wilcox NS, Huang A, Levy R, Demissei B, Narayan V, Ky B. Bearing allostatic load: insights into a more equitable future within cardio-oncology. Trends Mol Med. 2022 Dec;28(12):1040-1049. doi: 10.1016/j.molmed.2022.09.006. Epub 2022 Oct 4.
- Individual participant dataSharing planned: No
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kevin Volpp, MD, PhD principal investigator
University of Pennsylvania
Alexander C. Fanaroff, MD principal investigator
University of Pennsylvania
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Gamification and Social Support in people with Cardiovascular Diseases and Breast Cancer, run by Abramson Cancer Center at Penn Medicine at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in daily step count (time frame: Baseline to the 6-month intervention period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05176756, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2025.